Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 95 full-time employees. The firm is focused on developing treatments for severe inflammation and autoimmune diseases. Its product pipeline includes Inebilizumab, VIB4920 and VIB7734. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. VIB4920 is a fusion protein designed to bind to CD40 ligand (CD40L) on activated T cells, blocking the interaction with CD40 expressed on B cells and preventing them from differentiating into plasma cells and memory B cells. VIB7734 is a treatment for autoimmune and related inflammatory diseases.